---
document_datetime: 2023-09-21 22:27:08
document_pages: 25
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/novomix-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: novomix-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 16.2639374
conversion_datetime: 2025-12-22 11:12:17.171727
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## NovoMix

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IG/1621              | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information | 20/06/2023                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0115            | C.I.7.a - Deletion of - a pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22/05/2023   |     | SmPC, Annex II, Labelling and PL   |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|------------------------------------|-----------------------------------|
| PSUSA/1749/ 202209 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 14/04/2023   | n/a |                                    | PRAC Recommendation - maintenance |
| WS/2351            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                       | 09/02/2023   | n/a |                                    |                                   |
| WS/2302/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.e - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of an in-process test which may have a significant effect on the overall quality of the AS B.I.a.4.e - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of an in-process test which may have a significant effect on the overall quality of the AS | 15/12/2022   | n/a |                                    |                                   |
| PSUSA/1749/ 202109 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 05/05/2022   | n/a |                                    | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| WS/2106            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished product                            | 02/09/2021   | n/a   |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IB/0110/G          | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                              | 16/07/2021   | n/a   |                                   |
| WS/2056            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.c.3.a.2 - Change in source of an excipient or reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or reagents USED in the manufacture of a biol/immunol AS or in a biol/immunol medicinal product | 10/06/2021   | n/a   |                                   |
| PSUSA/1749/ 202009 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                                                                                                                                      | 06/05/2021   | n/a   | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0105            | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                             | 22/10/2020   | n/a        |                                  |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------|
| WS/1901            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                      | 24/09/2020   | 19/10/2021 | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/1749/ 201909 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                      | 17/04/2020   | n/a        |                                  | PRAC Recommendation - maintenance |
| IG/1184            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                     | 07/02/2020   | n/a        |                                  |                                   |
| IG/1172            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                     | 16/01/2020   | n/a        |                                  |                                   |
| WS/1687            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 05/12/2019   | n/a        |                                  |                                   |
| IG/1167            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                     | 22/11/2019   | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0099          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                         | 19/08/2019   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1092            | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                        | 12/07/2019   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| PSUSA/1749/ 201809 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                                                                                               | 26/04/2019   | 01/07/2019 |             | Based on the post-marketing data submitted within this PSUR, the PRAC concludes that anaphylactic reactions should be added to section 4.8 of the SmPC for Fiasp, in line with the SmPC for NovoRapid and NovoMix. Following 7 new reported cases of medically confirmed systemic allergic reactions for Fiasp and the already established evidence suggesting a causal relationship between insulin aspart and anaphylactic reactions, the updates to the section 4.8 of SmPC for Fiasp are justified. |
| WS/1564            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 04/04/2019   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0095            | Update of sections 4.2 and 4.5 of the SmPC to include data on the use of NovoMix 30 in combination with GLP-1 receptor agonists. The PL is                                                                                                                                                                                                                 | 31/01/2019   | 13/03/2019 | SmPC and PL | NovoMix 30 can also be given in combination with GLP-1 receptor agonists. GLP-1 receptor agonists may reduce the patient ' s insulin requirements. In patients with type 2                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                    | updated accordingly. The RMP is also updated (version 3.1). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                             |            |            |             | diabetes, a dose reduction of 20% is recommended for patients with an HbA1c less than 8% when a GLP-1 receptor agonist is added to NovoMix 30, to minimise the risk of hypoglycaemia. For patients with an HbA1c higher than 8% a dose reduction should be considered. Subsequently, dosage should be adjusted individually.   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1405            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 19/07/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                |
| PSUSA/1749/ 201709 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                              | 12/04/2018 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                              |
| IB/0093            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                            | 11/04/2018 | 13/03/2019 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                |
| IG/0897            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                          | 19/03/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                |
| IB/0090            | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)                                                         | 05/10/2017 | n/a        |             |                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| WS/1132            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                        | 05/05/2017   | n/a        |                              |                                                                                                                                                                                                                |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1749/ 201609 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                                                                                                                                                                | 05/05/2017   | n/a        |                              | PRAC Recommendation - maintenance                                                                                                                                                                              |
| II/0087            | Update of section 4.4 of the SmPC to include a warning on the risk of accidental mix-ups/medication errors. The package leaflet has been updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 15/12/2016   | 18/12/2017 | SmPC, Annex II and Labelling | Avoidance of accidental mix-ups/medication errors. Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between NovoMix and other insulin products. |
| PSUSA/1749/ 201509 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                                                                                                                                                                | 14/04/2016   | n/a        |                              | PRAC Recommendation - maintenance                                                                                                                                                                              |
| N/0083             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                            | 20/01/2016   | 12/12/2016 | Labelling and PL             |                                                                                                                                                                                                                |
| IG/0642            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                  | 21/12/2015   | 12/12/2016 | Annex II and PL              |                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IG/0644            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/12/2015   | n/a        |             |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------------|
| IB/0082            | B.II.h.z - Adventitious Agents Safety - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 04/09/2015   | n/a        |             |                                   |
| PSUSA/1749/ 201409 | Periodic Safety Update EU Single assessment - insulin aspart                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 07/05/2015   | n/a        |             | PRAC Recommendation - maintenance |
| II/0080/G          | This was an application for a group of variations. Update of section 4.4 of the SmPC in order to update the safety information regarding neutralising antibodies upon request by PRAC following the assessment of the RMP for insulin aspart. In addition the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. In the type IA variation, the MAH proposed to update the ATC code in section 5.1 of the SmPC. A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 24/07/2014   | 13/11/2014 | SmPC and PL |                                   |
| WS/0428            | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/05/2014   | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

|         | Commission Regulation (EC) No 1234/2008. to introduce changes to the active substance manufacturing process B.I.a.z - Change in manufacture of the AS - Other variation                                                                                                                                                              |            |            |                                  |                                                                                                                                                                                                                                                               |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0437 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 23/01/2014 | n/a        |                                  |                                                                                                                                                                                                                                                               |
| II/0077 | Update of the product information to implement the QRD version 9 and to harmonise the product information with other insulins from the same MAH. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                   | 21/11/2013 | 13/11/2014 | SmPC, Annex II, Labelling and PL | The MAH has updated the product information to make the text compliant with the latest QRD template and to improve the linguistics. In addition, some text proposals are made to harmonise Novomix with other products in the Novo Nordisk product portfolio. |
| N/0075  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                     | 30/07/2013 | 13/11/2014 | PL                               |                                                                                                                                                                                                                                                               |
| IA/0076 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                        | 26/07/2013 | n/a        |                                  |                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IG/0280   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                          | 17/04/2013   | n/a        |    |      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|------|
| II/0073/G | This was an application for a group of variations. To introduce an additional manufacturing site for the finished product. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 19/07/2012   | 19/07/2012 |    | site |
| N/0071    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                        | 20/03/2012   | 13/11/2014 | PL |      |
| IAIN/0072 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                      | 30/01/2012   | n/a        |    |      |
| IG/0137   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                     | 16/12/2011   | n/a        |    |      |
| IA/0069   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                           | 11/11/2011   | n/a        |    |      |

<div style=\"page-break-after: always\"></div>

| IB/0068/G   | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                          | 28/10/2011   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0067     | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 28/04/2011   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| WS/0091     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Further to a CHMP request based on the recommendations from PhVWP, the Product Information (Summary of Product Characteristics section 4.4 and Package Leaflet section 2) is updated by adding a warning on an increased incidence of heart failure when pioglitazone is used in combination with insulin, especially in patients with predisposing factors. In addition to the above the MAH took the opportunity to update annex IIB \"Other conditions\" with the latest wording as per October 2010 CHMP announcment regarding the Pharmacovigilance | 17/02/2011   | 17/03/2011 | SmPC, Annex II and PL | The PhVWP was requested to consider whether the increased risk of fluid retention and exacerbation of heart failure with the concomitant use of pioglitazone and insulin should apply to all centrally authorised insulin products. After the review of the available evidence, during its October 2010 meeting the PhVWP has concluded this review with a recommendation to the CHMP on the need to harmonise the SmPC and PL for all insulin products by including appropriate warning. The CHMP endorsed this recommendation, and in this context the Committee agreed that all centrally authorised insulin containing products should include warning on increased cardiac failure when pioglitazone is used in combination with insulin, especially in patients with predisposing factors in the in the section 4.4 of the SmPC and section 2 of the PL. Annex IIB \"Other conditions\" was also updated with the |

<div style=\"page-break-after: always\"></div>

|           | system. This application was submitted for a group of variations consisting of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH   |            |            |       | latest wording as per October 2010 CHMP announcment regarding the Pharmacovigilance system.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------|-----------------------------------------------------------------------------------------------|
| IB/0066/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line)            | 06/12/2010 | n/a        |       |                                                                                               |
| IB/0065   | B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS                                                                                                                                                                                                                                           | 04/11/2010 | n/a        |       |                                                                                               |
| IB/0063/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                           | 05/10/2010 | 05/10/2010 | SmPC, |                                                                                               |

<div style=\"page-break-after: always\"></div>

|         | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes   |            |            | Labelling and PL   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|
| II/0061 | To introduce changes in the manufacturing site of the active substance. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                   | 23/09/2010 | 29/09/2010 |                    |
| IA/0064 | B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information                                                                                                                                                                                                                                                                                                                                                                                                        | 14/09/2010 | n/a        | PL                 |
| IA/0062 | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging -                                                                                                                                                                                                                                                                                                                                                                                                                  | 01/08/2010 | n/a        | SmPC and PL        |

<div style=\"page-break-after: always\"></div>

|         | Device with CE marking                                                                                                                                                                                                                                                  |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0060  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                 | 22/04/2010 | 02/07/2010 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0059 | IA_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec.                                                                                                                                                                    | 02/11/2009 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0058 | Amendment of sections 4.4 and 4.5 of the SPC following the assessment of PSU 048, to introduce information on travelling and rewording the information on interactions. The PL is amended accordingly. Update of Summary of Product Characteristics and Package Leaflet | 24/09/2009 | 13/10/2009 | SmPC and PL                      | Following a CHMP request during the assessment of PSU 048 (01-Nov-2006 to 30-Sep-2008), the MAH introduced the following changes to the Summary of Product Characteristics: - Addition of a sentence in section 4.4 on the potential need to adjust the time of administration and meals while travelling between different time zones. - Rewording of the information on interactions (section 4.5) and inclusion of reference to the interaction with growth hormone. The Package Leaflet is updated accordingly. |
| II/0057 | Addition of an alternative manufacturing site for the specified finished products. Update of or change(s) to the pharmaceutical documentation                                                                                                                           | 24/09/2009 | 13/10/2009 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0056 | IA_25_b_01_Change to comply with Ph. - compliance with EU Ph. update - active substance                                                                                                                                                                                 | 01/07/2009 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0055 | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                    | 05/05/2009 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0054 | To change the status of specified products                                                                                                                                                                                                                              | 23/04/2009 | 28/04/2009 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | manufacturing sites from single product to multi product facilities. Change(s) to the manufacturing process for the finished product                                                                               |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0053 | Extension of the shelf-life of the drug substance. Quality changes                                                                                                                                                 | 19/02/2009 | 26/02/2009 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0051 | The Marketing Authorisation Holder applied for the addition of a new manufacturing site for the drug product. Change(s) to the manufacturing process for the finished product                                      | 20/11/2008 | 26/11/2008 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0052 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                           | 01/09/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0047 | Change(s) to the manufacturing process for the active substance                                                                                                                                                    | 24/07/2008 | 29/07/2008 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0049 | To update sections 4.2 and 5.1 of the SPC to include information regarding the transfer from biphasic human insulin to biphasic insulin aspart 30 Update of Summary of Product Characteristics and Package Leaflet | 26/06/2008 | 28/07/2008 | SmPC and PL | This variation concerns the update of sections 4.2 and 5.1 of the Summary of Product Characteristics (SPC) for NovoMix, to include information on transfer from biphasic human insulin 30 (BHI 30) to NovoMix 30 (BIAsp 30). These changes were supported by two clinical trials (038 and 1466) and an additional meta-analysis. Overall, In patients with type 2 diabetes a meta-analysis showed a reduced risk of overall nocturnal hypoglycaemic |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                |            |            |                  | episodes (symptoms of low blood sugar) and major hypoglycaemia with NovoMix 30 compared to biphasic human insulin 30. The risk of overall daytime hypoglycaemic episodes was increased in patients treated with NovoMix 30.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0043 | To update section 4.2 of the SPC following the assessment of the MAHs application to include a three times daily regimen for NovoMix 30 in the dosing guideline. In addition, minor changes to section 4.2 and 4.6 has been made. Update of Summary of Product Characteristics | 24/04/2008 | 19/06/2008 | SmPC             | The CHMP reviewed the results from four clinical trials (1707, 1325, 1554 and 2174) that studied three times daily regimen with NovoMix 30. From an efficacy point of view, the CHMP did not consider that the data submitted supports the TID regimen in type 2 diabetes patients with advanced diabetes who have failed to achieve good metabolic control on oral antidiabetics. However, the TID regimen may have a potential to lower the frequency of hypoglycaemias in patients requiring high doses of insulin. The CHMP therefore considered that the wording\"If twice daily dosing with NovoMix 30 results in recurrent daytime hypoglycaemic episodes, the morning dose can be split into morning and lunchtime doses (thrice daily dosing).\" is supported by the data and therefore is acceptable. |
| II/0048 | Change to the test procedure and/or specification of a raw material                                                                                                                                                                                                            | 30/05/2008 | 05/06/2008 |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0050 | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                           | 07/05/2008 | n/a        |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0042 | Change(s) to container                                                                                                                                                                                                                                                         | 19/03/2008 | 18/04/2008 | Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| N/0045  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                               | 17/03/2008 | n/a        | Labelling        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| N/0044   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                      | 17/03/2008   | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0041  | Change(s) to the manufacturing process for the finished product                                                                                                                                                                                                                                                                                       | 24/01/2008   | 30/01/2008 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0040  | Update of sections 4.2, 5.1 and 5.2 of the Summary of Product Characteristics (SPC) to include information about paediatric use. The Package Leaflet (PL) has been amended accordingly. Minor editorial changes were also made throughout all of the product information. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 15/11/2007   | 18/12/2007 | SmPC, Labelling and PL | The Marketing Authorisation Holder (MAH) submitted in this variation three main clinical trials (studies 1240, 1073 and 1459) evaluating the efficacy and safety of NovoMix 30 in children and adolescents (6 to 17 years of age) with type 1 diabetes. The MAH also submitted a retrospective trial (study 1676) which provides data from children and adolescents treated with insulin aspart (IAsp) over a period of 30 months. Upon evaluation of the submitted data, the CHMP was of the view that the use of premixed insulin may be beneficial for some children as it reduces the number of injections. However, based on the results from the submitted studies, the efficacy of NovoMix 30 in the treatment of children younger than 10 years could not be considered as sufficiently established. There were no unexpected safety signals in the submitted studies, and there were indications that NovoMix 30 may be associated with less weight gain and less hypoglycaemia compared to human insulin. However, long-term safety data in children and adolescents are missing. Thus, the CHMP concluded that the product information for |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                    |            |            |                                  | above 10 years, but that the benefit-risk balance for the use of NovoMix 30 in children younger than 10 years could not be considered as positive at the present time.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0039 | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                                     | 15/11/2007 | 21/11/2007 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0038 | Inclusion of the combination use of Novomix 30 with any oral antidiabetics (OAD) for which the combination with insulin is authorised. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 19/07/2007 | 27/08/2007 | SmPC, Annex II, Labelling and PL | Novomix 30 is already authorized for use in combination with metformin for the treatment of type 2 diabetes. To extend the use of Novomix 30 in combination with any OAD for which the combination with insulin is authorised, the MAH submitted the results of studies investigating Novomix 30 in combination with either metformin + sulphonylurea, or pioglitazone, or metformin + pioglitazone. Overall, the addition of Novomix 30 to ongoing treatment with metformin, pioglitazone or a combination of these compounds resulted in clinically relevant reductions of HbA1c. Incidence of weight gain and oedema was higher with the regimen of NovoMix 30 and thiazolidinedione (TZD) together than with TZD, TZD-OAD combinations or NovoMix 30 alone. In the litterature the use of this combination has also been associated with an increased incidence of cardiac failure. Therefore, patients should be observed for signs and symptoms of heart failure, weight gain and oedema when NovoMix 30 is used in combination with pioglitazone. |
| II/0036 | Change(s) to the manufacturing process for the active substance                                                                                                                                                    | 24/05/2007 | 29/05/2007 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0035 | Change(s) to the manufacturing process for the finished product                                                                                                                                                    | 22/03/2007 | 24/04/2007 | SmPC, Labelling and              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|         | Change in formulation Update of Summary of Product Characteristics, Labelling and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0037 | IA_28_Change in any part of primary packaging material not in contact with finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/03/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0034 | Change(s) to the manufacturing process for the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 16/11/2006 | 27/11/2006 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0033 | Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16/11/2006 | 27/11/2006 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0032 | IB_25_a_02_Change to comply with Ph. - compliance with EU Ph. - excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 25/04/2006 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0031 | The MAH applied with this variation for an update of the product information to include a dosing guidance for the product to assist practitioners in starting up and optimising the treatment based on a combination of clinical practice and results from relevant clinical experience available from the three trials included in this application. This implied revisions to section 4.2 and 5.1 of the SPC and relevant sections of the PL. In addition, minor amendments to harmonise the NovoMix30, NovoMix50 and NovoMix70 product information have been introduced together with additional details as how to store and discard the products. Update of Summary of Product Characteristics, | 23/02/2006 | 29/03/2006 | SmPC, Labelling and PL | The MAH submitted with this application clinical data from two controlled trials randomised, multi-centre, open-label parallel group trials designed to evaluate short-term efficacy and safety of BIAsp 30 initiation in people with type 2 diabetes who were insulin nave and inadequately controlled on current OHA therapy. A third trial was included as a supportive trial. This was an open-label, multi-centre, consecutive, three-phase, observational trial with no comparator. The objective of this trial was to evaluate the applicability of a step-wise therapeutic approach to insulin therapy with NovoMix30 similar to standard clinical practice. The main trial triggering the update of the product information is a study with patients with type 2 diabetes, |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | Labelling and Package Leaflet                                                                                                                                                                                                            |            |            |                        | insufficiently controlled on oral hypoglycaemic agents alone, were randomised to treatment with twice daily NovoMix 30 (117 patients) or once daily insulin glargine (116 patients). After 28 weeks treatment following the dosing guideline outlined in section 4.2 of the SPC, the mean reduction in HbA1c was 2.8% with NovoMix 30 (mean at baseline = 9.7%). With NovoMix 30, 66% and 42% of the patients reached HbA1c levels below 7% and 6.5%, respectively, and mean FPG was reduced by about 7 mmol/L (from 14,0 mmol/L at baseline to 7,1 mmol/L).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0019 | The present line extension application refers to two new premixed dosage forms of rapid-acting IAsp and protamine co-crystallised IAsp, biphasic insulin aspart 70 (BIAsp 70) Annex I_2.(c) Change or addition of a new strength/potency | 23/06/2005 | 05/10/2005 | SmPC, Labelling and PL | The present line extension application refers to a new premixed dosage forms of rapid-acting IAsp and protamine co-crystallised IAsp, biphasic insulin aspart 70 (BIAsp 70). BIAsp 70 have been developed to supplement the already marketed BIAsp 30. This will increase flexibility in treatment options, allowing for treatments tailored to the individual needs of people with type 1 or type 2 diabetes. Except for the limited number of points, which can be addresed as part of the post authorisation commitments, the quality of this new premixed dosage form is considered to be acceptable when used in accordance with the conditions in the SPC. The pivotal study demonstrated that a BIAsp three times daily regimen is a treatment alternative that can provide acceptable glycaemic control and that postprandial blood glucose elevations can be reduced if such a regimen is compared with a BHI 30 twice daily regimen. The efficacy of these new compositions has been sufficiently well demonstrated and the pharmacodynamic action/time profiles are in agreement with what could be expected from the amounts and properties of the two components. |

<div style=\"page-break-after: always\"></div>

|        |                                                                                                                                                                                                                                        |            |            |                        | The safety of BIAsp 70 has been sufficiently well characterised from a clinical point of view taking into account also the experience with pure soluble IAsp and BIAsp 30. The pattern of adverse events in the BIAsp treatment groups was similar to the pattern recorded in the BHI treated group in the pivotal study. The increased incidence of minor hypoglycaemic events among the BIAsp treated patients recorded in the pivotal study is most probably due to the higher total insulin doses and more frequent insulin administration as compared to the BHI treated patients. Please refer to Scientific Discussion:Novomix-H-308-X-19-SD                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0018 | The present line extension application refers to a new premixed dosage form of rapid-acting IAsp and protamine co-crystallised IAsp, biphasic insulin aspart 50 (BIAsp 50). Annex I_2.(c) Change or addition of a new strength/potency | 23/06/2005 | 05/10/2005 | SmPC, Labelling and PL | The present line extension application refers to a new premixed dosage form of rapid-acting IAsp and protamine co-crystallised IAsp, biphasic insulin aspart 50 (BIAsp 50). BIAsp 50 has been developed to supplement the already marketed BIAsp 30. This will increase flexibility in treatment options, allowing for treatments tailored to the individual needs of people with type 1 or type 2 diabetes. Except for the limited number of points, which can be addresed as part of the post authorisation commitments, the quality of this new premixed dosage form is considered to be acceptable when used in accordance with the conditions in the SPC. The pivotal study demonstrated that a BIAsp three times daily regimen is a treatment alternative that can provide acceptable glycaemic control and that postprandial blood glucose elevations can be reduced if such a regimen is compared with a BHI 30 twice daily regimen. The efficacy of these new compositions has been sufficiently well demonstrated and the pharmacodynamic action/time |

<div style=\"page-break-after: always\"></div>

|         |                                                                                |            |            |                                  | profiles are in agreement with what could be expected from the amounts and properties of the two components. The safety of BIAsp 50 has been sufficiently well characterised from a clinical point of view taking into account also the experience with pure soluble IAsp and BIAsp 30. The pattern of adverse events in the BIAsp treatment groups was similar to the pattern recorded in the BHI treated group in the pivotal study. The increased incidence of minor hypoglycaemic events among the BIAsp treated patients recorded in the pivotal study is most probably due to the higher total insulin doses and more frequent insulin administration as compared to the BHI treated patients. Please refer to Scientific Discussion:Novomix-H-308-X-18-SD   |
|---------|--------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0021 | Change(s) to the manufacturing process for the finished product                | 20/06/2005 | 10/08/2005 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0028 | Change(s) to the test method(s) and/or specifications for the active substance | 23/06/2005 | 08/07/2005 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0025 | Change(s) to the manufacturing process for the finished product                | 21/04/2005 | 10/06/2005 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0026 | Change(s) to the manufacturing process for the finished product                | 21/04/2005 | 12/05/2005 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0029 | IA_47_a_Deletion of a pharmaceutical form                                      | 23/03/2005 | n/a        | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0020 | Change(s) to the manufacturing process for the                                 | 16/03/2005 | 21/03/2005 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | finished product                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                 |                        |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------|
| N/0027  | Changes to include the increase in the dimensions of the Package Leaflet, and the outer packing material, as well as the introduction of an optimised blister packing material (introduction of air cushions to protect the cartridges) in accordance with article 61 (3) of Directive 2001/83/EC. Minor change in labelling or package leaflet not (Art. 61.3 Notification)                                                                        | 11/03/2005 | n/a        | PL              | connected with the SPC |
| IA/0024 | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                   | 20/12/2004 | n/a        | Annex II and PL |                        |
| IA/0023 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                                                                                                                                                                                                                                                                                      | 20/12/2004 | n/a        |                 |                        |
| X/0011  | X-1-iii_Qualitative change to the active substance(s)                                                                                                                                                                                                                                                                                                                                                                                               | 03/06/2004 | 24/08/2004 | Annex II        |                        |
| II/0015 | This variation concerns an update of section 4.2 and 5.1 of the Summary Product Characterstics and relevant section of the Package Leaflet (PL) to specify the use of NovoMix 30 in combination with metformin in patients with type 2 Diabetes mellitus that are insufficiently controlled on metformin alone. In addition, minor linguistic amendments are introduced in the PL. Update of Summary of Product Characteristics and Package Leaflet | 22/04/2004 | 07/07/2004 | SmPC and PL     |                        |

<div style=\"page-break-after: always\"></div>

| IB/0017   | IA_37_a_Change in the specification of the finished product - tightening of specification limits                                                                                                                                                                                                                                                          | 22/06/2004   | n/a        |                 |                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------|
| II/0016   | Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                                                                                | 22/04/2004   | 27/04/2004 |                 |                 |
| II/0013   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                          | 26/02/2004   | 15/04/2004 | SmPC and PL     |                 |
| II/0012   | The Marketing Authorisation Holder applied for a revision of the Summary of Product Characteristics and Package Leaflet (PL) to standardise the product information text for all Novo Nordisk A/S insulin products, and to reflect in the PL the results of the readability tests performed for Mixtard. Update of Summary of Product Characteristics and | 26/02/2004   | 15/04/2004 | SmPC and PL     | Package Leaflet |
| II/0014   | Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                                                                                | 24/03/2004   | 30/03/2004 |                 |                 |
| I/0009    | 20_Extension of shelf-life as foreseen at time of authorisation                                                                                                                                                                                                                                                                                           | 08/08/2003   | 08/10/2003 | SmPC            |                 |
| I/0010    | 15_Minor changes in manufacture of the medicinal product                                                                                                                                                                                                                                                                                                  | 25/09/2003   | 02/10/2003 |                 |                 |
| I/0008    | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process                                                                                                                                                                                                                                                            | 16/07/2003   | 22/08/2003 | Annex II and PL |                 |

<div style=\"page-break-after: always\"></div>

| II/0006   | Change(s) to the test method(s) and/or specifications for the active substance                 | 21/02/2002   | 28/02/2002   |                        |               |
|-----------|------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|---------------|
| I/0007    | 12_Minor change of manufacturing process of the active substance                               | 21/02/2002   | 28/02/2002   |                        |               |
| II/0005   | Change(s) to the test method(s) and/or specifications for the active substance Quality changes | 17/01/2002   | 28/01/2002   |                        |               |
| I/0004    | 11_Change in or addition of manufacturer(s) of substance                                       | 20/09/2001   | 08/10/2001   |                        | active        |
| II/0001   | New presentation(s)                                                                            | 19/10/2000   | 22/01/2001   | SmPC, Labelling and PL |               |
| I/0003    | 20_Extension of shelf-life as foreseen at time of                                              | 30/10/2000   | 22/01/2001   | SmPC                   | authorisation |